Six women with acne and six women with hirsutism were treated with the GnRH analog [D-Ser(But)6] LHRH-(1–9)ethylamide (Buserelin®) for 6 months (nasal spray, 1,200 μg/day) to suppress ovarian steroidogenesis. All women were eumenorrheic and did not demonstrate any adrenal or ovarian dysfunction. During treatment, ovarian steroids, LH and FSH decreased, while DHEA-S showed minor modifications; the clinical score for both acne and hirsutism showed a significant reduction. Moreover, acne and hirsutism were still well controlled 6 months after therapy. Gonadal function resumed in all patients after discontinuation of therapy. Three patients suffered from hot flashes from the 4th month. These data demonstrate that suppression of ovarian steroid secretion might be an efficient treatment in women suffering from acne or idiopathic hirsutism, indicating that ovarian steroids may have a key-role in the pathogenesis of these conditions.
Rittmaster R.S., Thompson D.L. Effect of Leuprolide and Dexamethasone on hair growth and hormone levels in hirsute women: the relative importance of the ovary and the adrenal in the pathogenesis of hirsutism. J. Clin. Endocrinol. Metab. 70: 1096, 1990.PubMedCrossRefGoogle Scholar
Andreiko J.L., Monroe S.E., Jaffe R.B. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin). J. Clin. Endocrinol. Metab. 63: 854, 1986.CrossRefGoogle Scholar
Matta W.H., Shaw R.W., Hesp R., Katz D. Hypogonadism induced by luteinizing releasing hormone agonist analogue: Effects on bone density in premenopausal women. Br. Med. J. 294: 1523, 1987.CrossRefGoogle Scholar
Johansen J.S., Riis B.J., Hassager C., Moen M., Jacobson J., Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism. J. Clin. Endocrinol. Metab. 67: 701, 1988.PubMedCrossRefGoogle Scholar
Riis B.J., Christiansen C., Johansen J.S., Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists? J. Clin. Endocrinol. Metab. 70: 920, 1990.PubMedCrossRefGoogle Scholar
Surrey E.S., Judd H.L Reduction of vasomotor symptoms and bone mineral density loss with combined norethindrone and long-acting Gonadotropin-releasing hormone agonist therapy of symptomatic endometriosis: a prospective randomized trial. J. Clin. Endocrinol. Metab. 75: 558, 1992.PubMedGoogle Scholar